Free tool
FAERS Monitor: Paragard T 380a
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018680 or its brand name (Paragard T 380a, Copper). Reports on generic versions are filed under their own applications.
Reports
43,152
Serious
19,749
46% of reports
Hospitalization
765
Death reported
60
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device breakage11,399
- device expulsion11,259
- complication of device removal10,261
- foreign body in reproductive tract8,905
- complication of device insertion8,360
- device dislocation7,298
- pain6,048
- embedded device4,782
- reproductive complication associated with device3,566
- emotional distress3,129
- anxiety3,117
- off label use2,864
- pelvic pain2,679
- procedural pain2,642
- muscle spasms2,563
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 11 |
| 2008 | 110 |
| 2009 | 58 |
| 2010 | 139 |
| 2011 | 187 |
| 2012 | 65 |
| 2013 | 40 |
| 2014 | 243 |
| 2015 | 3,156 |
| 2016 | 3,078 |
| 2017 | 3,430 |
| 2018 | 1,080 |
| 2019 | 7,055 |
| 2020 | 3,507 |
| 2021 | 3,298 |
| 2022 | 2,204 |
| 2023 | 4,300 |
| 2024 | 3,086 |
| 2025 | 3,247 |
| 2026 | 4,850 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,007 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| reproductive complication associated with deviceSignal | 3,566 | 868155.0 | 217040.6 | 1,735,139 |
| foreign body in reproductive tractSignal | 8,905 | 92253.3 | 69272.3 | 4,314,397 |
| complication of device removalSignal | 10,261 | 637.7 | 620.2 | 2,826,249 |
| embedded deviceSignal | 4,782 | 453.6 | 436.6 | 1,118,327 |
| complication of device insertionSignal | 8,360 | 352.2 | 343.0 | 1,700,293 |
| device breakageSignal | 11,399 | 189.8 | 186.2 | 1,543,449 |
| device expulsionSignal | 11,259 | 102.2 | 100.3 | 935,073 |
| device dislocationSignal | 7,298 | 98.1 | 95.8 | 584,902 |
| pelvic painSignal | 2,679 | 84.1 | 80.8 | 187,684 |
| procedural painSignal | 2,642 | 51.2 | 49.2 | 117,780 |
| emotional distressSignal | 3,129 | 12.9 | 12.5 | 33,659 |
| muscle spasmsSignal | 2,563 | 6.9 | 6.6 | 12,830 |
| anxietySignal | 3,117 | 5.4 | 5.2 | 11,159 |
| painSignal | 6,048 | 4.8 | 4.7 | 18,770 |
| off label use | 2,864 | 1.6 | 1.5 | 663 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.